comparemela.com

ஸ்டான்லி ஏற்க்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novavax s NanoFlu Influenza Vaccine Phase 3 Trial Meets All Primary Endpoints

BEIJING (dpa-AFX) - Novavax Inc. (NVAX) said that a complete results from a pivotal phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix-M

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.